1. Home
  2. NKLR vs ALT Comparison

NKLR vs ALT Comparison

Compare NKLR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKLR

Terra Innovatum Global N.V. Ordinary shares

N/A

Current Price

$5.58

Market Cap

500.6M

Sector

Industrials

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.41

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKLR
ALT
Founded
2018
1997
Country
Italy
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
500.6M
421.5M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
NKLR
ALT
Price
$5.58
$3.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$15.00
$17.67
AVG Volume (30 Days)
476.2K
2.5M
Earning Date
04-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$3.73
$2.87
52 Week High
$12.43
$7.73

Technical Indicators

Market Signals
Indicator
NKLR
ALT
Relative Strength Index (RSI) 62.76 47.73
Support Level $3.94 $3.40
Resistance Level $5.73 $3.54
Average True Range (ATR) 0.40 0.16
MACD 0.14 0.06
Stochastic Oscillator 73.62 80.60

Price Performance

Historical Comparison
NKLR
ALT

About NKLR Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: